{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:50:16Z","timestamp":1783032616889,"version":"3.54.6"},"reference-count":22,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1183\/23120541.00372-2024","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:56:06Z","timestamp":1721638566000},"page":"00372-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterogeneity in non-cystic fibrosis bronchiectasis: insights from ASPEN trial participants"],"prefix":"10.1183","volume":"10","author":[{"given":"Melissa H.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-8149","authenticated-orcid":false,"given":"Shijing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2024101706280076000_10.4.00372-2024.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra012519"},{"key":"2024101706280076000_10.4.00372-2024.2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101706280076000_10.4.00372-2024.3","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.060889"},{"key":"2024101706280076000_10.4.00372-2024.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00119114"},{"key":"2024101706280076000_10.4.00372-2024.5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"2024101706280076000_10.4.00372-2024.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2024101706280076000_10.4.00372-2024.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024101706280076000_10.4.00372-2024.8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00151-2024"},{"key":"2024101706280076000_10.4.00372-2024.9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cpt.1053","article-title":"Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects","volume":"104","author":"Palm\u00e9r","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024101706280076000_10.4.00372-2024.10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jpha.2022.12.003","article-title":"Neutrophil elastase: from mechanisms to therapeutic potential","volume":"13","author":"Zeng","year":"2023","journal-title":"J Pharm Anal"},{"key":"2024101706280076000_10.4.00372-2024.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2024101706280076000_10.4.00372-2024.12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101706280076000_10.4.00372-2024.13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir Res"},{"key":"2024101706280076000_10.4.00372-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00695-2022"},{"key":"2024101706280076000_10.4.00372-2024.15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024101706280076000_10.4.00372-2024.16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the us bronchiectasis research registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"key":"2024101706280076000_10.4.00372-2024.17","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","article-title":"Bronchiectasis in India: results from the European multicentre bronchiectasis audit and research collaboration (EMBARC) and respiratory research network of india registry","volume":"7","author":"Dhar","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2024101706280076000_10.4.00372-2024.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.07.016"},{"key":"2024101706280076000_10.4.00372-2024.19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/resp.14059","article-title":"Characteristics of bronchiectasis in Korea: first data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries","volume":"26","author":"Lee","year":"2021","journal-title":"Respirology"},{"key":"2024101706280076000_10.4.00372-2024.20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2024101706280076000_10.4.00372-2024.21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biomedicines9070772","article-title":"T2-high endotype and response to biological treatments in patients with bronchiectasis","volume":"9","author":"Oriano","year":"2021","journal-title":"Biomedicines"},{"key":"2024101706280076000_10.4.00372-2024.22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1329"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00372-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:38:42Z","timestamp":1740375522000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00372-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1183\/23120541.00372-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00372-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}